Lupin receives UK MHRA Approval of Lutio for treatment of COPD

Lutio has the potential to offer significant cost savings when available to UK patients.

Lupin and I'rom signs licensing agreement for Denosumab biosimilar for Japan

Pristyn Care witnesses industry highest adoption of EMR

99% of Pristyn Doctors are using EMR facility on its doctor app

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients

Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim

The cash consideration for the above acquisition will be Euro 26 million.

Merck gets fast track designation from the USFDA for anticoagulant therapy

Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis

Lessons from COVID management valuable beacons for cancer prevention and treatment: Union Health Secretary

The pandemic has taught us that health is not the exclusive responsibility of only the Union Health Ministry but jointly addressed by various Ministries at the centre and through state governments

PGIMER Satellite Centre to be functional by Jan 2023: Dr. Mandaviya

Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked

8th edition of Indo-Japanese Chronic Total Occlusion (IJCTO) summit concluded successfully

The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO

DCGI approves AstraZeneca 's Olaparib film-coated tablets

Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer